Active Biotech Ab

Chelsea Therapeutics, Inc.

Ingela Fritzson

Stephen East

Leif Svensson

David Liberg

Natacha Prevost

Colin MacKinnon

Ulf Vellmar

Ingrid Hallin

Leif Svenson

Helén Tuvesson Andersson

Ulf Wellmar

Stig Jönsson

Gunnar Andersson

A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between SI 00A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.

N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors

A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders. 

Compounds of formula (I) are provided, wherein X is CH&#x2550;CH, CHO wherein the oxygen atom is bound to ring B, or OCHwherein the oxygen atom is bound to ring A; Y is hydrogen, straight or branched C1-C6 alkyl or a pharmaceutically acceptable inorganic cation; R1 is ethyl or cyclopropyl; and R2 and R3 are the same or different and are selected from F, Cl, Br, CFand OCF. The compounds are useful for the treatment of autoimmune diseases, inflammatory diseases, organ transplant rejection, and malignant neoplasia. Pharmaceutical compositions containing the compounds, methods of using the compounds, and methods for preparing the compounds are also provided.

Anthranilic acid derivatives

Compounds of formula (I) are provided, wherein X is CH&#x2550;CH, CHO wherein the oxygen atom is bound to ring B, or OCHwherein the oxygen atom is bound to ring A; Y is hydrogen, straight or branched C1-C6 alkyl or a pharmaceutically acceptable inorganic cation; R1 is ethyl or cyclopropyl; and R2 and R3 are the same or different and are selected from F, Cl, Br, CFand OCF. The compounds are useful for the treatment of autoimmune diseases, inflammatory diseases, organ transplant rejection, and malignant neoplasia. Pharmaceutical compositions comprising the compounds, methods of using the compounds, and methods for preparing the compounds are also provided.

Compounds of formula (I) for clinical treatment of autoimmune diseases, inflammatory diseases, organ transplant rejection and malignant neoplasia. A pharmaceutical composition comprising a compound of formula (I) in an amount giving a daily dosage of from 0.005 mg/kg to 10 mg/kg body weight, in particular from 0.025 mg/kg to 2 mg/kg body weight.

Growing community of inventors

Lund, Sweden

Ingela Fritzson